series-b
Stage
1
Investors
About
Cellectis is a biopharmaceutical company specializing in gene-editing technologies for the development of immunotherapies based on engineered CAR-T cells.
Explore Cellectis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.